(CNTX) Context Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US21077P1084

CNTX: Cancer, Therapy, Antibody, Treatment

Context Therapeutics Inc. (NASDAQ:CNTX) is a biopharmaceutical company focused on developing innovative treatments for solid tumors. Its lead candidate, CTIM-76, is a bispecific antibody targeting Claudin 6 (CLDN6) and CD3, designed to direct T-cell-mediated killing of cancer cells expressing CLDN6. Claudin 6 is a tight junction protein overexpressed in various cancers, making it a promising target for anticancer therapies. The company leverages a collaboration with Integral Molecular, Inc. to advance its CLDN6 bispecific antibody program. Founded in 2015, Context Therapeutics is based in Philadelphia, Pennsylvania, a hub for biotech innovation. The company’s approach combines cutting-edge antibody engineering with a focus on unmet medical needs in oncology.

From a technical standpoint, CNTX has shown a decline in price over the past 200 days, with the SMA 200 at $1.75 compared to the current price of $0.84. The stock is trading below its SMA 50 ($0.94) and SMA 20 ($0.84), indicating bearish momentum. The average trading volume over 20 days is 122,097 shares, with an ATR of $0.10, suggesting low volatility. The stock’s current price reflects a challenging environment for early-stage biotech companies, where valuations are often tied to clinical trial outcomes and regulatory milestones.

On the fundamental side, Context Therapeutics has a market capitalization of $60.76 million, with a price-to-book ratio of 0.76, indicating that the stock is trading below its book value. The company’s return on equity (RoE) is -35.96%, reflecting significant R&D investments and operating losses typical of clinical-stage biotech firms. With no current revenues, the company’s valuation is heavily dependent on the success of its pipeline, particularly CTIM-76.

3-Month Forecast: Based on the technical and fundamental data, CNTX is expected to remain under pressure in the near term. The stock’s price could consolidate near current levels or potentially test lower support zones due to weak momentum indicators. However, any positive updates on CTIM-76 or its collaboration with Integral Molecular could act as catalysts for a rebound. Fundamental risks include dilution from potential financing activities and ongoing R&D expenses. The stock’s low average volume and tight ATR suggest limited near-term volatility, but the overall bearish trend in the biotech sector may continue to weigh on sentiment.

Additional Sources for CNTX Stock

CNTX Stock Overview

Market Cap in USD 60m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2021-10-20

CNTX Stock Ratings

Growth 5y -53.9%
Fundamental -
Dividend 0.0%
Rel. Strength Industry -37
Analysts 4.4/5
Fair Price Momentum 0.59 USD
Fair Price DCF -

CNTX Dividends

No Dividends Paid

CNTX Growth Ratios

Growth Correlation 3m -92.3%
Growth Correlation 12m -38.1%
Growth Correlation 5y -25%
CAGR 5y -44.11%
CAGR/Max DD 5y -0.47
Sharpe Ratio 12m -1.27
Alpha -44.19
Beta 0.55
Volatility 96.25%
Current Volume 129.9k
Average Volume 20d 75.4k
What is the price of CNTX stocks?
As of March 15, 2025, the stock is trading at USD 0.71 with a total of 129,912 shares traded.
Over the past week, the price has changed by -11.90%, over one month by -14.07%, over three months by -48.09% and over the past year by -36.40%.
Is Context Therapeutics a good stock to buy?
No, based on ValueRay Analyses, Context Therapeutics (NASDAQ:CNTX) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -53.85 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CNTX as of March 2025 is 0.59. This means that CNTX is currently overvalued and has a potential downside of -16.9%.
Is CNTX a buy, sell or hold?
Context Therapeutics has received a consensus analysts rating of 4.40. Therefor, it is recommend to buy CNTX.
  • Strong Buy: 2
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CNTX stock price target?
According to ValueRays Forecast Model, CNTX Context Therapeutics will be worth about 0.6 in March 2026. The stock is currently trading at 0.71. This means that the stock has a potential downside of -9.86%.
Issuer Forecast Upside
Wallstreet Target Price 7.1 897.2%
Analysts Target Price 7.7 984.5%
ValueRay Target Price 0.6 -9.9%